4-Boc-氨甲基哌啶 | 135632-53-0

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-Boc-氨甲基哌啶
• 中文别名: N-(4-哌啶甲基)氨基甲酸叔丁酯；4-BOC-氨基甲基-哌啶；4-N-BOC-氨甲基哌啶；N-BOC-4-甲氨基哌啶；4-(叔丁氧羰基氨基甲基)哌啶；4-(Boc-氨甲基)哌啶
• 英文名称: tert-butyl N-(4-piperidinylmethyl)carbamate
• 英文别名: tert-butyl (piperidin-4-ylmethyl)carbamate；tert-butyl N-(4-piperidylmethyl)carbamate；4-(Boc-aminomethyl)piperidine；4-(tert-butoxycarbonylaminomethyl)piperidine；tert-butyl N-(piperidin-4-ylmethyl)carbamate；1,1-dimethylethyl [(piperidin-4-yl)methyl]carbamate；piperidin-4-ylmethylcarbamic acid tert-butyl ester；tert-butyl 4-piperidinylmethylcarbamate；4-(N-boc-aminomethyl)piperidine；(boc-4-aminomethyl)-piperidine
• CAS: 135632-53-0
• 化学式: C₁₁H₂₂N₂O₂
• mdl: MFCD01631214
• 分子量: 214.308
• InChiKey: VHYXAWLOJGIJPC-UHFFFAOYSA-N

物化性质

• 熔点：
  106 °C
• 沸点：
  321.8±15.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  8
• 安全说明：
  S26,S36/37/39,S45
• 危险品运输编号：
  UN3259
• 海关编码：
  2933399090
• 危险品标志：
  C
• 危险类别码：
  R34
• 包装等级：
  Ⅲ
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H315,H319
• 储存条件：
  冷藏保存。

SDS

Name:	tert-Butyl N-(4-piperidinylmethyl)carbamate 97% Material Safety Data Sheet
Synonym:
CAS:	135632-53-0

Section 1 - Chemical Product MSDS Name:tert-Butyl N-(4-piperidinylmethyl)carbamate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
135632-53-0	tert-Butyl N-(4-piperidinylmethyl)carb	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 135632-53-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 153 - 154 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H22N2O2
Molecular Weight: 214

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes, ammonia.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 135632-53-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl N-(4-piperidinylmethyl)carbamate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 135632-53-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 135632-53-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 135632-53-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

4-Boc-氨甲基哌啶包含一个哌啶环和一个氨基甲基，并且氨基甲基上带有叔丁氧羰基（tert-butoxycarbonyl，简称Boc）保护基。这种化合物常被用作有机合成中的中间体。叔丁氧羰基是一种常见的保护基，在有机合成反应中可以保护胺基不发生不需要的反应。通过加入叔丁氧羰基保护基，可以在需要还原胺基之前，防止其参与其他化学反应。在适当条件下，可以通过去除叔丁氧羰基来还原胺基。

合成方法

将4-氨基甲基哌啶（242mg，2.12mmol）和二碳酸二叔丁酯（Boc2O，463mg，2.12mmol）溶解于二氯甲烷（5mL）中，在室温下搅拌过夜。随后加入二氯甲烷稀释并用饱和盐水洗涤，再经过无水硫酸钠干燥、过滤和减压浓缩，最终得到4-Boc-氨甲基哌啶。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯	tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate	173340-23-3	C18H28N2O2	304.433

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(1-Isopropyl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester	534595-60-3	C14H28N2O2	256.389
  ——	tert-butyl {[1-(ethoxymethyl)piperidin-4-yl]methyl}carbamate	871021-86-2	C14H28N2O3	272.388
  ——	1,1-dimethylethyl {[1-(tetrahydro-2H-pyran-4-ylmethyl)-4-piperidinyl]methyl}carbamate	935696-99-4	C17H32N2O3	312.453
  ——	4-[4-(tert-butoxycarbonylaminomethyl)piperidin-1-ylmethyl]-piperidine-1-carboxylic acid methyl ester	916076-13-6	C19H35N3O4	369.505
  ——	tert-butyl ((1-(oxetan-3-yl)piperidin-4-yl)methyl)carbamate	1349708-81-1	C14H26N2O3	270.372
  ——	ethyl 3-(4-{[(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)propanoate	908139-87-7	C16H30N2O4	314.425
  ——	tert-butyl ((1-(methylsulfonyl)piperidin-4-yl)methyl)carbamate	1286272-93-2	C12H24N2O4S	292.4
  ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯	tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate	173340-23-3	C18H28N2O2	304.433
  ——	[1-(tetrahydro-pyran-4-carbonyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester	1286273-83-3	C17H30N2O4	326.436
  ——	(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tBu ester	534595-64-7	C16H25N3O2	291.393

反应信息

• 作为反应物：
  描述：

  4-Boc-氨甲基哌啶 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 1-苄基哌啶-4-甲胺
  参考文献：
  名称：

  具有 PARP-1 和胆碱酯酶抑制活性的新型酞嗪酮衍生物的合成及初步生物学评价

  摘要：

  背景：阿尔茨海默氏病 (AD) 是最常见的脑部疾病，并且仍然是全世界的主要健康问题。考虑到 AD 的高度复杂机制，寻找基于多靶点定向配体 (MTDLs) 策略治疗 AD 的药物可能比传统的“一种药物-一种靶点”策略更有前景。抑制聚（ADP-核糖）聚合酶-1 (PARP-1) 对 AD 具有潜在的治疗作用。因此，值得研究同时靶向 PARP-1 和胆碱酯酶的化合物，这可能会产生新的抗 AD 药物。目的：寻找具有 PARP-1 和胆碱酯酶抑制活性的新药治疗 AD。方法：一系列 21 种新化合物结合了两种上市药物的各自药效团，即 PARP-1 抑制剂的 4-苄基酞嗪酮部分，Olaparib 和 AChE 抑制剂多奈哌齐的 Nbenzylpiperidine 部分被合成到一个分子中。评估了所有合成化合物对酶 PARP-1、乙酰胆碱酯酶 (AChE) 和丁酰胆碱酯酶 (BChE) 的抑制活性。通过分子对接研究了

  DOI：

  10.2174/1570180819666220531144809
• 作为产物：
  描述：

  哌啶-4-甲酰胺 在 lithium aluminium tetrahydride 、 palladium hydroxide, 20 wt% on carbon 、 三乙胺 、 环己烯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 51.0h， 生成 4-Boc-氨甲基哌啶
  参考文献：
  名称：

  基于晶体结构的抑制剂优化的魔力：具有皮摩尔亲和力和体内活性的丁酰胆碱酯酶抑制剂的开发

  摘要：

  大脑中丁酰胆碱酯酶（BChE）的酶活性随阿尔茨海默氏病的发展而增加，因此将BChE归类为晚期阿尔茨海默氏病的有希望的药物靶标。我们使用基于结构的药物发现方法来开发有效的，选择性的和可逆的人类BChE抑制剂。最有效的化合物3由于与阳离子B相互作用强，因此与BChE具有皮摩尔的抑制常数，这是由其与人BChE的复合物的晶体结构解析得出的。另外，化合物3离体抑制BChE并且是无细胞毒性的。体外药代动力学实验表明，化合物3具有高蛋白结合性，高渗透性和代谢稳定性。最后，化合物3跨越血脑屏障，并且在东pol碱痴呆模型中改善了小鼠的记忆，认知功能和学习能力。因此，化合物3是用于开发减轻晚期阿尔茨海默氏病患者的胆碱能功能减退症状的药物的有希望的先进先导化合物。

  DOI：

  10.1021/acs.jmedchem.7b01086
• 作为试剂：
  描述：

  1-(3-chloropropyl)-1H-1,2,3-triazole 、 4-Boc-氨甲基哌啶 在 4-Boc-氨甲基哌啶 作用下， 以100的产率得到tert-butyl [[1-{3-(1H-1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]carbamate
  参考文献：
  名称：

  Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate

  摘要：

  本发明涉及一种制备N-[[1-{3-(1,2,3-三唑-1-基)丙基}哌啶-4-基]甲基]-4-氨基-5-氯-2-甲氧基苯甲酰胺的方法，该化合物是一种5-HT4受体激动剂的新型苯甲酰胺衍生物，或其药学上可接受的盐；涉及一种用于制备该化合物的新型中间体；以及一种制备该中间体的方法。本发明的制备方法可用于大规模生产，因为使用了低价试剂和中间体，并且反应过程的数量减少，从而节省了制备成本并提高了产率。

  公开号：

  US09771348B2

文献信息

• PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
  申请人：Arora Nidhi

  公开号：US20120015962A1

  公开（公告）日：2012-01-19

  Compounds of the formula I or II: wherein X, m, Ar, R 1 and R 2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式I或II的化合物： 其中X，m，Ar，R1和R2如本文所定义。所述化合物对于治疗IRAK介导的疾病是有用的。
• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2010115688A1

  公开（公告）日：2010-10-14

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• [EN] SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO<br/>[FR] COMPOSÉS PYRAZOLE ET PYRROLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CES DERNIERS POUR L'INHIBITION DE L'INITIATION DE LA TRADUCTION ET LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À CETTE DERNIÈRE
  申请人：BANTAM PHARMACEUTICAL LLC

  公开号：WO2016196644A1

  公开（公告）日：2016-12-08

  Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

  揭示了吡唑化合物，以及其药物组合物和使用方法。其中一种实施例是具有结构（I）及其药用可接受的盐和/或氧化物，其中X1、X2、Z1、Z2、由“a”表示的环系统、R1、A1A、L1B、A1B、L1A、L2、Q、L3、R3、A4A、L4B、A4B、L4A、R4、L5和R5如本文所述。在某些实施例中，本文所披露的化合物破坏elF4E/eiF4G相互作用，并可用于治疗过度增殖性疾病、神经系统疾病或障碍，或自闭症。
• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• Substituted Indole Compounds
  申请人：Schunk Stefan

  公开号：US20100222324A1

  公开（公告）日：2010-09-02

  Substituted indole compounds corresponding to the formula I: In which R 8 , R 9a , R 9b , R 10 , R 11 , R 200 , R 210 , A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

  将与下式I对应的吲哚化合物替代： 其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义，其制备方法，含有这种化合物的药物组合物以及用于治疗或抑制至少部分由Bradykinin 1受体（B1R）介导的疼痛和其他病症的替代吲哚化合物的用途。